SUMMARY An investigation of cell-mediated cytotoxicity in 22 patients with systemic lupus erythematosus (SLE), using both whole blood and purified peripheral blood mononuclear cells (PBM) to measure antibody-dependent (ADCC) and phytohaemagglutinin (PHA)-induced lymphocyte cytotoxicity for Chang liver cells, has revealed 2 distinct abnormalities in patients with active disease. PHA-induced cytotoxicity was found to be selectively reduced in whole blood assays only (P<0.05), whereas ADCC was impaired in both whole blood (P=0-02) and PBM (P<0.05) assays, when comparison was made with 52 normal controls. The addition of patients' sera to corresponding assays utilising control PBM confirmed that the impaired PHA-induced cytotoxicity resulted from circulating inhibitory serum factors. Surprisingly little effect, however, was exerted on ADCC assays. These findings suggest that there is a reduction in numbers and/or functional capacity of Fc-receptor cells in active SLE, which may have pathogenetic implications.
Although peripheral blood lymphocyte subpopulations'2 and mitogen responsiveness>5 have been extensively studied in systemic lupus erythematosus (SLE), cell-mediated cytotoxic mechanisms have received comparatively little attention. The few studies of spontaneous lymphocyte cytotoxicity for cultured target cells have produced conflicting reports of both increased6 and normal cytotoxicity,7 while investigation of antibody-dependent cellular cytotoxicity (ADCC) has revealed the presence of impaired responses in patients with active disease8 9 when Chang liver cells were used as targets. In the present study we have extended investigation into both ADCC and phytohaemagglutinin (PHA)-induced lymphocyte cytotoxicity for Chang liver cells in SLE in relation to both the severity of the disease and the modifying effect of the patient's serum.
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Materials and methods PATIENT AND CONTROL GROUPS Twenty-two patients (21 women; 1 man; mean age 42 1, SD years) with SLE who had either 4 criteria of the American Rheumatism Association'0 or 3 criteria and a positive test for DNA antibodies were investigated. Untreated patients with clinically active disease were particularly selected for comparison with patients on treatment and in remission. Thirteen patients (12 women; 1 man; mean age 41 -2, SD 13 2 years) were judged to have clinically active disease with varying combinations of fever, serositis, nephritis, arthritis, anaemia, and neurological manifestations, and only 4 of these were receiving treatment (prednisolone 5-15 mg/day in 4; azathioprine 100 mg/day in 1) at the time of their initial tests. Nine patients (all women; mean age 43-2, SD 9 9 years) were in remission, and all these were on treatment (prednisolone 5-15 mg/day in 8; azathioprine 25 mg/day in 1). Controls consisted of 52 healthy volunteers (25 women; 27 men; mean age 39 9, SD 14-7 years Lymphocytotoxins. These were detected by a microcytotoxicity test13 using B and T cells isolated by the differential centrifugation of SRBC-rosetted lymphocytes obtained from 4 normal donors of differing HLA type. Cytotoxicity was assessed after a 2-stage test, in which patients' sera and test lymphocytes were incubated for 1 h at 370C, 180C, and 40C respectively, followed by the addition of rabbit complement and a further 2 h incubation at 250C.
Lymphocyte subpopulations. T and B lymphocytes were estimated by the formation of T rosettes with SRBC and by immunofluorescence staining of surface immunoglobulin respectively as previously described."
STATISTICAL METHODS
The cytotoxicity data were analysed by the MannWhitney ranking test.14 The relationship between cytotoxicity in whole blood and PBM assays was examined by regression analysis following logarithmic conversion of the data. (Fig. 1 ). There was a good correlation for ADCC between whole blood and PBM assays in controls (r=0-69, P<0 001, Fig. 2 ), and this relationship persisted in patients with SLE with both inactive (r=0 71, P<0*05, Fig. 3 ) and active disease (r=0 68, P<0*01, Fig. 4 Fig. 2 The relationship between antibody-dependent lymphocyte cytotoxicity for Chang liver cells (20 000/ml) using both whole blood (200 il) and peripheral blood mononuclear cells (500 000/ml) in normal controls (r== 0-69, P<0 001). Fig. 4 The relationship between antibody-dependent lymphocyte cytotoxicity for Chang liver cells (20 000/ml) using both whole blood (200 tAd) and peripheral blood mononuclear cells (500 000/ml) in patients with active systemic lupus erythematosus (r= 0*68, P< 0 -01).
(0) Patient on immunosuppressive drugs.
SERUM ADDITION EXPERIMENTS
The effect of sera from patients with both active and inactive SLE and normal controls on ADCC and PHA-induced cytotoxicity is summarised in Figs 9 and 10.
In ADCC the addition of lupus sera had, surprisingly, little effect on the cytotoxicity produced by normal control lymphocytes; only 1 serum from a patient with active disease produced a marked reduction in cytotoxic response (Fig. 9) .
By contrast, in PHA-induced cytotoxicity 8 of the 14 lupus sera tested produced a marked reduction in the response of normal control lymphocytes. The effect was particularly noticeable in the sera of patients with active disease, as 6 of the 9 patients in this subgroup had sera that produced marked inhibition of PHA-induced cytotoxicity (Fig. 10) .
PERIPHERAL BLOOD MONONUCLEAR CELLS SPECIFIC CYTOTOXICITY (LOG10) Fig. 3 The relationship between antibody-dependent lymphocyte cytotoxicity for Chang liver cells (20 000/ml) using both whole blood (200 (Fig. 11) . There was also a significant reduction of B lymphocytes, which was again, restricted to patients with active disease (P<0-05). 13 11 Inactive SLE Chang liver cells. The simultaneous use of both whole blood and PBM as effector systems in these assays has been important in revealing the quite distinctive nature of these 2 defects of lymphocyte function.
In PHA-induced lymphocyte cytotoxicity, which is mediated predominantly by T lymphocytes,'5 16 the impaired responses found in whole blood assays in patients with active disease are likely to result from the presence of inhibitory serum factors, as the corresponding assays using PBM showed no parallel reduction of cytotoxicity. Further confirmation of the presence of circulating inhibitory factors was provided by the finding that a high proportion of sera from patients with active SLE also produced a marked reduction in PHA-induced cytotoxicity in control PBM.
Although the origin of these serum effects requires further investigations, sera from patients with SLE frequently contain factors capable of inhibiting various aspects of lymphocyte function in vitro. A lymphokine-like substance which inhibited PHAinduced lymphocyte cytotoxicity in a chicken red blood cell system has been described previously in the sera of patients with active disease. 17 The possibility of antilymphocyte antibodies causing such inhibition also exists as lymphocytotoxins, some of which may show a relative specificity for T lymphocytes, have been described in SLE. 18 In the present study such lymphocytotoxins showed an association with disease activity but did not correlate with the inhibition of PHA-induced lymphocytotoxicity detected either in whole blood assays or in the serum addition experiments. However, the sera of patients with active SLE may also contain 
